Grants for State governments - Health

This grant provides funding for multidisciplinary teams, including researchers, industry partners, and patient advocates, to develop innovative genetic therapies for rare hereditary diseases affecting millions of Americans, particularly children, by creating safe and effective one-time treatments.

The "Blueprint MedTech Translator" grant aims to fund researchers to develop and test therapeutic and diagnostic devices for nervous or neuromuscular system disorders, with support for clinical trials, safety testing, design verification, and regulatory approvals, while also providing access to expert consultants and specialized research organizations.

The Statewide Family Network Program aims to enhance the capacity of statewide mental health family-controlled organizations. These organizations engage with family members and primary caregivers who are raising children, youth, and young adults with serious emotional disturbance (SED) and/or co-occurring disorders (COD). The program supports family-driven, trauma-informed, culturally relevant, holistic, and resiliency-oriented approaches. Eligible applicants include states and territories, political subdivisions of states, Indian tribes or tribal organizations, health facilities, and other public or private non-profit entities. Applications are due by April 8, 2024, with awards expected to start by September 30, 2024. The grant provides up to $120,000 per year for up to three years, with a total available funding of $1,116,777. Nine awards are anticipated. Cost sharing or matching is not required.

This grant provides funding to college and university students in the U.S. to create projects that promote unity and dialogue among diverse student groups in response to civic tensions following the 2024 election.

The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism. The model formulation parameters and relevant physiology should be informed with suitable in vitro and in vivo experiments. A suitable preclinical animal model can be used to validate the PBPK model based IVIVCs for both LAI suspensions and polymer based implants. The use of PBPK modelling provides a unique opportunity to understand how the physicochemical properties of drug molecules/polymer, implant specific properties, critical formulation attributes, and physiology, among other things, influence the in vivo release mechanisms of LAI drug products and their disposition characteristics. Moreover, once developed, a mechanistic PBPK model can help to define the 'safe space' for critical formulation attributes relevant to the reference listed drug (RLD) product, explain sources of PK variability and extrapolate predictions to human subjects by leveraging animal model data and by accounting for species-specific physiological differences.

This initiative provides state public health departments with a collaborative platform to enhance brain health and support caregivers through knowledge-sharing and technical assistance, without direct funding.

The National Academy of Sciences Gulf Research Program is investing $50 million in the Gulf Futures Challenge to fund projects addressing critical challenges in the Gulf region. The Challenge aims to discover and promote innovative and transformative solutions by leveraging the talent and knowledge of the Gulf's people. The competition focuses on three main areas: energy transition, environmental change along the coast, and healthy and resilient communities. Up to ten finalists will receive up to $1 million in project development support, with two finalists awarded $20 million each to implement their solutions. Eligible applicants include nonprofits, state, local, and tribal governments, and academic institutions from Alabama, Florida, Louisiana, Mississippi, or Texas, with projects located within 100 miles of the Gulf coastline. The registration deadline is August 20, 2024, and the application deadline is September 20, 2024.

This funding opportunity supports research projects that develop and implement effective tobacco use treatment services for cancer survivors across diverse clinical settings, with a focus on equitable access and reducing health disparities.

This funding opportunity supports graduate students from diverse backgrounds in neuroscience to complete their Ph.D. and transition into postdoctoral research positions, promoting career development and research training.

This funding opportunity provides financial support to organizations developing medical respite programs that offer short-term care for individuals experiencing homelessness who need a safe place to recover from illness or injury.

This funding opportunity provides financial support for early-career researchers from diverse backgrounds to develop their skills in cancer research under the mentorship of experienced scientists, without leading independent clinical trials.

This grant provides funding for research to develop and test combined neuromodulation and behavioral treatment strategies for individuals with Stimulant Use Disorder, particularly targeting those with vulnerable traits like low executive function and impulsivity.

This funding opportunity supports research to improve stem cell-derived islet cells for transplantation therapies, targeting interdisciplinary collaborations among scientists and institutions focused on diabetes and cell biology.

The purpose of this program is to provide trauma-informed, evidence-based interventions to youth and young adults (not more than 25 years of age) who are at clinical high risk for psychosis. Award recipients are expected to use evidence-based intervention to: 1) improve symptomatic and behavioral functioning; (2) enable youth and young adults to resume age-appropriate social, academic, and/or vocational activities; (3) delay or prevent the onset of psychosis; and (4) minimize the duration of untreated psychosis for those who develop psychotic symptoms.

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.

NLM wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes.NLM wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes. This Funding Opportunity Announcement is focused on automating curation of biomedical digital assets in support of Goal 1. Objective 1.1 of the NLM Strategic Plan 2017-2027: An important research direction will develop strategies for curation at scale." The ability to re-use, integrate or add to existing data sets will open new avenues of opportunity and can speed discoveries that will improve health. But this promise will go unrealized without advances in automated and autonomous curation. Objective 1.2: Automatic, autonomous curation strategies will allow for operational efficiency as well as accelerate the speed of discovery Digital curation involves characterizing, annotating, managing, and preserving digital assets such as research data sets, computational and other types of models, reusable visualization tools, and other digital assets. Proficient curation of digital assets maximizes their reuse potential, mitigates risk of obsolescence, reduces the likelihood that their long-term value will diminish or be lost, and helps assure reproducibility of research. The evolving digital ecosystem supports data-driven biomedical discovery by providing access to large quantities of biomedical and health-related data, to computational models and to open source software and code. The scope, scale and heterogeneity of digital data alone are vast, ranging from genome sequences to biomedical images, from observational health findings to environmental measurements, from family histories to sensor readings from personal trackers. As the amount and complexity of digital assets continue to grow, manual curation will not scale to meet future needs. At the same time, as researchers make research data sets, models and other tools available for new uses or re-analysis, it is important to minimize duplication and simplify the process of finding, managing, visualizing and mining all types of digital assets. To help researchers who want to find, interoperate and use these data sources to make new discoveries, and to share their findings so others can build upon them, the purpose of this funding announcement is to encourage applications for new approaches that (1) increase the speed and assure quality and security of storage techniques, retrieval strategies, annotation methods, data standards, visualization tools and other advanced data management approaches and (2) improve our ability to make biomedical data and other digital research assets findable, accessible, interoperable and reusable (FAIR).

Research shows that HIV care must increasingly address the management of individuals with multiple coexisting diseases (p.357) such as infectious and chronic diseases, mental health and behavioral disorders, food insecurity, substance use, etc. Since individual diseases do not exist in a vacuum, neither does the management, or burden of disease on community well-being. In response, syndemic theory and approaches are used to (1) increase the focus on co-occurring and interacting disease and social conditions that exacerbate health inequities, and (2) advance the evidence base for effective approaches to assess, monitor, and intervene with respect to these co-occurring and interacting factors for optimal outcomes in HIV treatment and care. The purpose of this project is to design, implement, and evaluate innovative comprehensive interventions part of an integrated treatment plan , using a syndemic approach to address co-occurring and interacting conditions of HIV, substance use disorder, intimate partner violence (IPV), and other social determinants of health that impact health outcomes of racial and ethnic minorities with HIV.

The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions

This grant provides funding for researchers to develop and test advanced imaging tracers that can help understand and treat mental health and neurodegenerative disorders in humans.

The purpose of this initiative is to: 1.Support mining of SCORCH data to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/ART or SUD molecular responses 2.Support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening, etc.) to confirm or deny a biological role for data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART or SUD molecular responses 3.Provide foundational knowledge for understanding SUD and/or HIV/ART molecular mechanisms and to generate validated targets that could serve as a foundation for new SUD or HIV therapeutics (including NeuroHIV cognitive phenotypes)